RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

Special systems were developed for response assessment of immunooncology drugs. The role and benefits of particular system in assessing the efficacy of different immunotherapy methods are not clear yet. The objective of this study is to compare the responses on ipilimab (IPI) or dendritic cell vacci...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Novik, E. V. Yaremenko, E. M. Anokhina, T. L. Nehaeva, A. I. Semenova, D. Kh. Latipova, S. A. Protsenko, I. A. Baldueva
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2019-09-01
Series:Сибирский онкологический журнал
Subjects:
melanoma
ipilimumab
dendritic cell vaccines
recist 1.1
irrc
response assessment
immunotherapy
Online Access:https://www.siboncoj.ru/jour/article/view/1136
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items